Skip to content
Cephradine
Anspor, Velosef (cephradine) is a small molecule pharmaceutical. Cephradine was first approved as Velosef on 1982-01-01. It is used to treat bacterial infections, bacterial skin diseases, escherichia coli infections, klebsiella infections, and proteus infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cephradine
Tradename
Company
Number
Date
Products
VELOSEFBristol Myers SquibbN-050530 DISCN1982-01-01
1 products
VELOSEF '250'ErsanaN-050548 DISCN1982-01-01
1 products
VELOSEF '500'ErsanaN-050548 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
bacterial skin diseases—D017192—
escherichia coli infectionsEFO_1001318D004927B96.20
klebsiella infectionsEFO_1001353D007710—
proteus infectionsEFO_1001130D011512—
respiratory tract infections—D012141J06.9
soft tissue infections—D018461—
staphylococcal infections—D013203A49.01
streptococcal infectionsEFO_1001476D013290—
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DB: First-generation cephalosporins
— J01DB09: Cefradine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEPHRADINE
INNcefradine
Description
Cephradine is a first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton. It has a role as an antibacterial drug. It is a cephalosporin and a beta-lactam antibiotic allergen.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1
Identifiers
PDB—
CAS-ID38821-53-3
RxCUI2239
ChEMBL IDCHEMBL1604
ChEBI ID3547
PubChem CID38103
DrugBankDB01333
UNII ID9YA6SX5S4D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,631 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details